PI Financial Lowers Price Target on Aurora Cannabis

Aurora Cannabis (TSX: ACB) (NYSE: ACB) saw PI Financial lower its price target today after the firm put out earnings with gross revenues of $271 million yesterday after hours. While maintaining a buy rating on the equity, PI Financial dropped its price target from $15.00 to $12.00.

The report contained a number of key items related to Aurora Cannabis, including that it is forecasting a plateauing of its revenues, which Aurora stated this morning on its earnings conference call. Referencing recreational markets, Aurora Cannabis placed the blame squarely on provincial regulators in key provinces and their poor roll out of retail outlets as the main reason behind the revenue plateau.

Within todays report, analyst Jason Zandberg states,”The drop is due to our EBITDA revision for FY21. We believe that ACB will maintain its leadership position in the Canadian market and deserves a premium trading multiple. Our target represents an EV/EBITDA multiple of 40x based on our FY21 EBITDA (previously 42x).” PI Financial still lists Aurora Cannabis as a ‘speculative’ risk.

Notably, PI Financial has steadily decreased its estimates in relation to Aurora Cannabis. In August of 2018, PI Financial was forecasting that the cannabis cultivator would see sales of $437 million for FY2019, and $954.9 million for FY2020. They also anticipated positive EBITDA of $75.8 million, and $296.3 million respectively. At the time, Zandberg had assigned a price target of $13.00 for the equity – notably, dilution at the time was also approximately 50% lower than current levels.

Looking towards the future, PI Financial has since lowered its revenue estimates for Aurora for FY2020, with revenues now expected to come in at $600 million for the year, with a positive EBITDA of $8.8 million. FY2021 is estimated to see significant revenue growth, with estimates of $1.09 billion in earnings, and a positive EBITDA of $303.7 million. FY2021 is also when Aurora Cannabis is expected to post an overall net income, with positive earnings of $0.07 per share.

Aurora Cannabis closed today’s session at $7.75 per share on the Toronto Stock Exchange, down 8.93% from the day prior.


Information for this briefing was found via PI Financial and Aurora Cannabis. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Antimony Resources Expands New Discovery Following Trenching

Silver47 Kicks Off 7,000-Meter Drill Campaign at Nevada’s Hughes Project

Related News

Aurora Cannabis Sued By CTT Pharma Over Denial Of Contractual Commitments

It seems Aurora Cannabis (TSX: ACB) (NYSE: ACB) has found itself in some hot water....

Thursday, August 27, 2020, 08:01:37 AM

Aurora Exports $10 Million In Cannabis To Israel

Aurora Cannabis (TSX: ACB) seemingly remains focused on growing its international medical cannabis operation. The...

Tuesday, January 4, 2022, 08:07:20 AM

Aurora Cannabis Posts Declining Q4 2021 Revenues Of $54.8 Million, Net Loss

Aurora Cannabis (TSX: ACB) this afternoon reported its fourth quarter financial results. The firm reported...

Monday, September 27, 2021, 06:16:23 PM

Aurora Cannabis, New Gold Amid Names Dropped From S&P/TSX Composite In Latest Rebalance

Details on the latest quarterly adjustments to the S&P/TSX Composite Index, as well as the...

Saturday, September 3, 2022, 11:11:00 AM

Aurora Cannabis: The Analysts Take On The Reliva Acquisition

A week after Aurora Cannabis (TSX: ACB) (NYSE: ACB) closed their U$40 million all-share deal...

Friday, June 5, 2020, 04:08:00 PM